GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Spectranetics Corp (NAS:SPNC) » Definitions » Debt-to-Equity

The Spectranetics (The Spectranetics) Debt-to-Equity : 8.25 (As of Jun. 2017)


View and export this data going back to 1992. Start your Free Trial

What is The Spectranetics Debt-to-Equity?

The Spectranetics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2017 was $26.2 Mil. The Spectranetics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2017 was $313.6 Mil. The Spectranetics's Total Stockholders Equity for the quarter that ended in Jun. 2017 was $41.2 Mil. The Spectranetics's debt to equity for the quarter that ended in Jun. 2017 was 8.25.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for The Spectranetics's Debt-to-Equity or its related term are showing as below:

SPNC's Debt-to-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.21
* Ranked among companies with meaningful Debt-to-Equity only.

The Spectranetics Debt-to-Equity Historical Data

The historical data trend for The Spectranetics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Spectranetics Debt-to-Equity Chart

The Spectranetics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.38 2.63 4.16

The Spectranetics Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.36 3.69 4.16 5.16 8.25

Competitive Comparison of The Spectranetics's Debt-to-Equity

For the Medical Devices subindustry, The Spectranetics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

The Spectranetics's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, The Spectranetics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where The Spectranetics's Debt-to-Equity falls into.


The Spectranetics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

The Spectranetics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(24.712 + 284.759) / 74.323
=4.16

The Spectranetics's Debt to Equity Ratio for the quarter that ended in Jun. 2017 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(26.162 + 313.628) / 41.192
=8.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Spectranetics  (NAS:SPNC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

The Spectranetics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of The Spectranetics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

The Spectranetics (The Spectranetics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Spectranetics Corp (NAS:SPNC) » Definitions » Debt-to-Equity
Comparable Companies
XSWX:MOVE INGN INSP HKSE:00853 CSII SZSE:300326 SHSE:688016 OSTO:SECT B HKSE:01789 INMD SZSE:300633 TSE:7779 TCMD SHSE:688139 VREX SILK SZSE:300298 TSE:6960 TSE:7575 SWAV
Traded in Other Exchanges
N/A
Address
Website
http://www.spectranetics.com
Spectranetics manufactures and sells single-use medical devices used in minimally invasive cardiovascular procedures. The firm operates in the three categories: vascular intervention, lead management, and laser, service, and other. The vascular intervention business contributes the majority of revenue and sells laser and aspiration catheters, balloon catheters, and support catheters. The lead management business sells devices used to remove pacemaker and defibrillator cardiac leads. The laser, service, and other business includes a laser system for cardiovascular procedures. Spectranetics generates the vast majority of its revenue in the United States.
Executives
Todd C Schermerhorn director C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
William C Jennings director 108 CHERRY HILL DRIVE, BEVERLY MA 01915-1053
B Kristine Johnson director 366 FERNDALE RD S, WAYZATA MN 55391
Scott William Drake director, officer: President, CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Shahriar Matin officer: Chief Operating Officer 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Stacy Powell Mcmahan officer: CFO 1000 CRANBERRY WOODS DRIVE, CRANBERRY TOWNSHIP PA 16066
Anne Melissa Dowling director 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Jonathan Will Mcguire officer: COO 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Stephen D Okland officer: Vice President of Sales 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Martin T Hart director 2401 EAST 2ND AVE., SUITE 250, DENVER CO 80206